Liu Y - Search Results

1

Enhancing therapeutic efficacy in homologous recombination-proficient pancreatic cancer via the combination of PARP1-PROTAC and a BRD4 inhibitor.

Pu C, Liu Y, Lan S, Fan H, Liu L, Liu J, Guo Y. Pu C, et al. Among authors: liu j, liu y, liu l. Bioorg Med Chem. 2024 Dec 1;115:117970. doi: 10.1016/j.bmc.2024.117970. Epub 2024 Oct 26. Bioorg Med Chem. 2024. PMID: 39476572

2

Synthesis and biological evaluation of a tumor-selective degrader of PARP1.

Pu C, Wang S, Luo D, Liu Y, Ma X, Zhang H, Yu S, Lan S, Huang Q, Deng R, He X, Li R. Pu C, et al. Among authors: liu y. Bioorg Med Chem. 2022 Sep 1;69:116908. doi: 10.1016/j.bmc.2022.116908. Epub 2022 Jun 26. Bioorg Med Chem. 2022. PMID: 35780655

3

Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.

Shan H, Ma X, Yan G, Luo M, Zhong X, Lan S, Yang J, Liu Y, Pu C, Tong Y, Li R. Shan H, et al. Among authors: liu y. Eur J Med Chem. 2021 Jul 5;219:113432. doi: 10.1016/j.ejmech.2021.113432. Epub 2021 Apr 3. Eur J Med Chem. 2021. PMID: 33857728

4

Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.

Pu C, Tong Y, Liu Y, Lan S, Wang S, Yan G, Zhang H, Luo D, Ma X, Yu S, Huang Q, Deng R, Li R. Pu C, et al. Among authors: liu y. Eur J Med Chem. 2022 Jun 5;236:114321. doi: 10.1016/j.ejmech.2022.114321. Epub 2022 Apr 3. Eur J Med Chem. 2022. PMID: 35430559

5

Discovery of 2-Methyl-2-(4-(2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-naphtho[1,2-d]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy In Vitro and In Vivo.

Yang J, Liu Y, Lan S, Yu S, Ma X, Luo D, Shan H, Zhong X, Yan G, Li R. Yang J, et al. Among authors: liu y. J Med Chem. 2022 Oct 13;65(19):12781-12801. doi: 10.1021/acs.jmedchem.2c00572. Epub 2022 Oct 3. J Med Chem. 2022. PMID: 36191148

6

Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.

Wang S, Luo D, Pu C, Ma X, Zhang H, Feng Z, Deng R, Yu S, Liu Y, Huang Q, Li R. Wang S, et al. Among authors: liu y. Eur J Med Chem. 2023 Feb 15;248:115082. doi: 10.1016/j.ejmech.2022.115082. Epub 2023 Jan 1. Eur J Med Chem. 2023. PMID: 36628851

7

Development of PROTAC degrader probe of CDK4/6 based on DCAF16.

Pu C, Liu Y, Deng R, Xu Q, Wang S, Zhang H, Luo D, Ma X, Tong Y, Li R. Pu C, et al. Among authors: liu y. Bioorg Chem. 2023 Sep;138:106637. doi: 10.1016/j.bioorg.2023.106637. Epub 2023 May 27. Bioorg Chem. 2023. PMID: 37276679

8

Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1.

Luo D, Luo R, Wang W, Deng R, Wang S, Ma X, Pu C, Liu Y, Zhang H, Yu S, Huang Q, Yang L, Tong Y, Zheng Y, Li R. Luo D, et al. Among authors: liu y. Bioorg Med Chem Lett. 2024 Oct 1;111:129880. doi: 10.1016/j.bmcl.2024.129880. Epub 2024 Jul 10. Bioorg Med Chem Lett. 2024. PMID: 38996941

9

Discovery of 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline as a novel c-myc inhibitor against colorectal cancer in vitro and in vivo.

Yang J, Cao C, Luo D, Lan S, Luo M, Shan H, Ma X, Liu Y, Yu S, Zhong X, Li R. Yang J, et al. Among authors: liu y. Eur J Med Chem. 2020 Jul 15;198:112336. doi: 10.1016/j.ejmech.2020.112336. Epub 2020 Apr 26. Eur J Med Chem. 2020. PMID: 32387836

10

Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis.

Zhong X, Luo R, Yan G, Ran K, Shan H, Yang J, Liu Y, Yu S, Pu C, Zheng Y, Li R. Zhong X, et al. Among authors: liu y. Eur J Med Chem. 2021 Nov 15;224:113680. doi: 10.1016/j.ejmech.2021.113680. Epub 2021 Jul 1. Eur J Med Chem. 2021. PMID: 34245947

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

205,156 results

Search Page

Filters